CDX Development Update
LONDON, UNITED KINGDOM / ACCESSWIRE / September 2, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO)(“Hemogenyx Pharmaceuticals” or the “Company”), a clinical-stage biopharmaceutical group focused on developing treatments for cancers and viral diseases, is pleased to announce that it has developed a new and improved version of its bi-specific antibody (“CDX”) for the treatment of relapsed/refractory acute myeloid leukaemia (“AML”), a subset of acute lymphoblastic leukaemia (“ALL”), and potentially for conditioning in bone marrow transplantations.
The Company’s scientists utilised Lonza’s bYlok bispecific pairing technology to develop a new and improved version of CDX, which has demonstrated significantly enhanced efficacy in in vitro testing. Additional in vivo studies are currently underway.
Dr. Vladislav Sandler, CEO and Co-Founder of Hemogenyx Pharmaceuticals, commented:
“The development of an improved version of our CDX bi-specific antibody holds significant promise for enhancing treatment outcomes for patients battling often incurable blood cancers. This advancement could accelerate the progress of this product candidate and allow us to resume its development toward the clinic. It may also attract new industry partners interested in fast-tracking the co-development of CDX.”
Enquiries:
Hemogenyx Pharmaceuticals plc | |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | |
Peter Redmond, Director | |
|
|
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
Matthew Johnson, Vadim Alexandre, Adam Cowl |
|
|
|
Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
Lucy Williams, Duncan Vasey, Charles Goodfellow |
|
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.
The Company is a clinical-stage biopharmaceutical group developing new medicines and treatments for life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.
About AML
AML, the most common type of acute leukemia in adults, has poor survival rates (a five-year survival rate of less than 30% in adults) and is currently treated using chemotherapy, rather than the potentially more benign and effective form of therapy being developed by Hemogenyx Pharmaceuticals. The successful development of the new therapy for AML would have a major impact on treatment and survival rates for the disease.
About ALL
Acute Lymphoblastic Leukemia (ALL) is a cancer of the blood and bone marrow that primarily affects children, although it can also occur in adults. Unlike Acute Myeloid Leukemia (AML), ALL is characterized by the rapid proliferation of immature lymphocytes, a type of white blood cell. ALL is the most common childhood cancer, representing approximately 25% of cancer diagnoses in children. It progresses quickly and requires prompt treatment. While the overall prognosis for ALL is generally more favorable than AML, certain subtypes remain challenging to treat. Hemogenyx Pharmaceuticals is developing innovative treatments specifically targeting a subset of ALL that has proven particularly difficult to treat, especially in children. The Company’s R&D focuses on addressing the limitations of current therapies and improving outcomes for patients with these hard-to-treat forms of ALL.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View the original press release on accesswire.com
